Latest Breaking News On - Emergency use listing nod from - Page 1 : comparemela.com

Covaxin was found to have 78% efficacy against COVID19 of any severity, 14 or more days after the second dose. Moreover, the WHO statement also remarked that the Covaxin is extremely suitable for low- and middle-income countries due to easy storage requirements. 📰 Covaxin, Bharat Biotech s COVID-19 Vaccine, Gets WHO Approval for Emergency Use Listing.

Mansukh mandviyaUnion healthStrategic advisory group of experts on immunizationWorld healthIndian council of medical researchWorld health organisationBio serum institute of indiaBharat biotechHyderabad based bharat biotechIndian councilEmergency use listing approval fromSerum instituteApproval meanSri lankaStrategic advisory groupEmergency use listing nod from